SFCC provides outsourced drug development research services Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SFCC provides outsourced drug development research services

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Skywatcher who wrote (3)	10/16/2001 7:24:38 PM
From: Skywatcher	Read Replies (1) of 29

Pharm Product (PPDI) 31.95 -0.79: Posts Q3 net of $0.22 a share, $0.01 better than consensus, vs yr-ago EPS of $0.17. Sales rose 21% to $108 mln (mean $106.7 mln). Separately, announces amendment to agreement with Eli Lilly (ELY); PPDI will receive payment from LLY for returning rights to a number of Lilly compounds in the genitourinary field; see press release. This should bode well for SFCC tomorrow.... Today was a GREAT day for the stock....with this one having good earnings and growing revenues, I am very optimistic that 2002 will be a good year for them. And there are always the rumors that PPDI may acquire them. Now that bio terror etc is such a big deal, it is logical to assume that both of these companies stand to benefit from lack of abililties of private drug and bio companies to do all their own research. CC

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next